MCID: LYM002
MIFTS: 40

Lymphoplasmacyte-Rich Meningioma

Categories: Cancer diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Lymphoplasmacyte-Rich Meningioma

MalaCards integrated aliases for Lymphoplasmacyte-Rich Meningioma:

Name: Lymphoplasmacyte-Rich Meningioma 12 15 17 72
Lymphoplasmocyte-Rich Meningioma 12
Meningioma 72

Classifications:



External Ids:

Disease Ontology 12 DOID:4591
NCIt 50 C4720
SNOMED-CT 68 19453003
UMLS 72 C0025286 C0431119

Summaries for Lymphoplasmacyte-Rich Meningioma

MalaCards based summary : Lymphoplasmacyte-Rich Meningioma, also known as lymphoplasmocyte-rich meningioma, is related to spinal meningioma and meningioma, familial. An important gene associated with Lymphoplasmacyte-Rich Meningioma is MIB1 (Mindbomb E3 Ubiquitin Protein Ligase 1), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Microglia Activation During Neuroinflammation: Microglia Polarization. The drugs Thrombin and Hemostatics have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and pituitary, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lymphoplasmacyte-Rich Meningioma

Diseases related to Lymphoplasmacyte-Rich Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 spinal meningioma 31.5 PGR MIB1
2 meningioma, familial 30.4 PGR CD68
3 meningioma, radiation-induced 10.9
4 secretory meningioma 10.9
5 rapidly involuting congenital hemangioma 10.9
6 rosai-dorfman disease 10.4
7 igg4-related disease 10.4
8 brain edema 10.4
9 idiopathic hypertrophic pachymeningitis 10.4
10 igg4-related pachymeningitis 10.4
11 hydrops, lactic acidosis, and sideroblastic anemia 10.3
12 headache 10.3
13 viral esophagitis 10.2 CD79A CD68
14 hodgkin's lymphoma, lymphocytic depletion 10.2 CD79A CD68
15 small intestine lymphoma 10.2 UCHL1 CD79A
16 ulcerative stomatitis 10.1 CD79A CD68
17 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.1
18 brain meningioma 10.1
19 fibrous dysplasia 10.1
20 optic nerve disease 10.1
21 hyperostosis 10.1
22 histiocytosis 10.1
23 jugular foramen meningioma 10.1
24 angiomatous meningioma 10.1
25 47,xyy 10.1
26 dysphagia 10.1
27 posttransplant acute limbic encephalitis 10.1
28 rare surgical neurologic disease 10.1
29 lichen nitidus 10.1 UCHL1 CD68
30 central nervous system sarcoma 10.1 CD68 CD163
31 spinal canal and spinal cord meningioma 10.1 PGR MIB1
32 granular cell tumor 10.1 UCHL1 CD68
33 adult xanthogranuloma 10.1 CD68 CD163
34 spleen cancer 10.1 CD68 CD163
35 petroclival meningioma 10.1 CD68 CD163
36 lymphatic system cancer 10.1 UCHL1 CD79A
37 photokeratitis 10.1 CD68 CD163
38 indeterminate leprosy 10.0 UCHL1 CD68
39 enterobiasis 10.0 CD68 CD163
40 calcific tendinitis 10.0 UCHL1 CD68
41 skin sarcoma 10.0 CD68 CD163
42 dysgerminoma of ovary 10.0 PGR CD79A
43 solitary osseous plasmacytoma 9.9 SDC1 CD79A
44 miliaria 9.8 SDC1 CD68
45 granulomatous endometritis 9.7 SDC1 PGR
46 reticulohistiocytic granuloma 9.7 UCHL1 CD68 CD163
47 mature b-cell neoplasm 9.7 SDC1 CD79A
48 synovitis 9.7 CD68 CD163
49 congenital epulis 9.6 UCHL1 PGR CD68
50 leukocyte disease 9.6 SDC1 CD79A

Graphical network of the top 20 diseases related to Lymphoplasmacyte-Rich Meningioma:



Diseases related to Lymphoplasmacyte-Rich Meningioma

Symptoms & Phenotypes for Lymphoplasmacyte-Rich Meningioma

GenomeRNAi Phenotypes related to Lymphoplasmacyte-Rich Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.17 CD163 CD79A
2 Decreased viability GR00381-A-2 9.17 CD163
3 Decreased viability GR00381-A-3 9.17 CD163 CD79A
4 Decreased viability GR00402-S-2 9.17 CD163 CD79A

MGI Mouse Phenotypes related to Lymphoplasmacyte-Rich Meningioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 CD163 CD68 CD79A MIB1 PGR SDC1
2 no phenotypic analysis MP:0003012 8.92 CD68 CD79A MIB1 PGR

Drugs & Therapeutics for Lymphoplasmacyte-Rich Meningioma

Drugs for Lymphoplasmacyte-Rich Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2 Hemostatics Phase 4
3 Coagulants Phase 4
4 Fibrin Tissue Adhesive Phase 4
5
Tranexamic Acid Approved Phase 3 1197-18-8 5526
6
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
7
Donepezil Approved Phase 3 120014-06-4 3152
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
10
Ondansetron Approved Phase 3 99614-02-5 4595
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Cisatracurium Approved Phase 3 96946-41-7
13
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
14
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
15
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
18
Histamine Approved, Investigational Phase 3 51-45-6 774
19
Cyproheptadine Approved Phase 3 129-03-3 2913
20
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Antifibrinolytic Agents Phase 3
23 Progestins Phase 3
24 Peripheral Nervous System Agents Phase 3
25 Cholinesterase Inhibitors Phase 3
26 Cholinergic Agents Phase 3
27 Nootropic Agents Phase 3
28 Liver Extracts Phase 3
29 Emetics Phase 3
30 Cola Phase 3
31 Anesthetics, Intravenous Phase 3
32 Narcotics Phase 3
33 Analgesics, Opioid Phase 3
34 Adjuvants, Anesthesia Phase 3
35 Anesthetics, General Phase 3
36 Analgesics Phase 3
37 Tocolytic Agents Phase 3
38 Central Nervous System Depressants Phase 3
39 Antihypertensive Agents Phase 3
40 Anesthetics Phase 3
41 Anti-Arrhythmia Agents Phase 3
42 Anticonvulsants Phase 3
43 Vasoconstrictor Agents Phase 3
44 calcium channel blockers Phase 3
45 Calcium, Dietary Phase 3
46 Gastrointestinal Agents Phase 3
47 Central Nervous System Stimulants Phase 3
48 Neurotransmitter Agents Phase 3
49 Dermatologic Agents Phase 3
50 Dexmethylphenidate Hydrochloride Phase 3

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
5 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
6 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
7 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
9 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
17 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
18 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
19 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Unknown status NCT01117844 Phase 1, Phase 2
20 Proton Radiation for Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
21 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
22 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
23 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
24 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Completed NCT00626730 Phase 2
25 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
26 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
27 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
28 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
29 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
30 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
31 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
32 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
33 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
34 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
35 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
36 A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas Completed NCT00004868 Phase 1, Phase 2 semaxanib
37 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
38 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
39 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
40 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
41 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
42 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
43 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
44 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
45 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 3 mg/kg;Nivolumab - 480 mg;Nivolumab - 1 mg/kg
46 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
47 A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation Recruiting NCT03071874 Phase 2 AZD2014
48 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Recruiting NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
49 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Recruiting NCT01849484 Phase 2
50 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2

Search NIH Clinical Center for Lymphoplasmacyte-Rich Meningioma

Genetic Tests for Lymphoplasmacyte-Rich Meningioma

Anatomical Context for Lymphoplasmacyte-Rich Meningioma

MalaCards organs/tissues related to Lymphoplasmacyte-Rich Meningioma:

41
Brain, Bone, Pituitary, Spinal Cord, Breast, Lung, Pineal

Publications for Lymphoplasmacyte-Rich Meningioma

Articles related to Lymphoplasmacyte-Rich Meningioma:

(show top 50) (show all 13707)
# Title Authors PMID Year
1
Bulky cardiac metastasis of intracranial solitary fibrous tumor/hemangiopericytoma: Delayed metastasis after cranial tumor resection. 38
31372191 2019
2
One-stage frame-guided resection and reconstruction with PEEK custom-made prostheses for predominantly intraosseous meningiomas: technical notes and a case series. 38
31055698 2019
3
Petroclival Meningioma Presenting With an Ipsilateral Sixth Nerve Palsy and a Contralateral Homonymous Quadrantanopia: A Unique and Topographically Localizing Syndrome. 38
30664101 2019
4
Papillary meningioma: Diagnosis by intraoperative crush smear cytology. 38
31074947 2019
5
Immunological and vascular characteristics in cavernous sinus meningioma. 38
31213381 2019
6
Impact of radiotherapy in atypical meningioma recurrence: literature review. 38
29552691 2019
7
Pediatric Rhabdoid Meningioma with Extension to the Heart: A First Case Report and Literature Review. 38
31247353 2019
8
Intramedullary Thoracic Meningioma: A Rare Case Report and Review of the Literature. 38
31146040 2019
9
Survival in Patients with High-Grade Spinal Meningioma: An Analysis of the National Cancer Database. 38
31203074 2019
10
Analysis of patterns of failure and appraisal of postoperative radiation field for grade II-III meningioma. 38
31278690 2019
11
EQ-5D Quality-of-Life Analysis and Cost-Effectiveness After Skull Base Meningioma Resection. 38
30869135 2019
12
Presurgical differentiation between malignant haemangiopericytoma and angiomatous meningioma by a radiomics approach based on texture analysis. 38
31226327 2019
13
Cancer incidence among workers with blood lead measurements in two countries. 38
31296664 2019
14
Malignant Meningioma: An International Multicentre Retrospective Study. 38
30566646 2019
15
Geriatric brain tumor management part I: Meningioma. 38
31208835 2019
16
Ventricular Meningiomas: Surgical Strategies and a New Finding That Suggest an Origin From the Choroid Plexus Epithelium. 38
31121376 2019
17
8-Year Follow-up for Woman with Spinal Meningeal Melanocytoma in S1 Nerve Root: Case Report and Literature Review. 38
31426249 2019
18
Comparison of ABC/2 estimation and a volumetric computerized method for measurement of meningiomas using magnetic resonance imaging. 38
31401721 2019
19
Letter to the Editor Regarding "Preoperative and Histological Predictors of Recurrence and Survival in Atypical Meningioma After Initial Gross Total Resection". 38
31426269 2019
20
Folate Receptor Overexpression in Human and Canine Meningiomas-Immunohistochemistry and Case Report of Intraoperative Molecular Imaging. 38
30113687 2019
21
Dural-Based Frontal Lobe Hemangioblastoma. 38
31150863 2019
22
Approach Selection and Surgical Planning in Posterior Cranial Fossa Meningiomas: How I Do It. 38
31316884 2019
23
Folate can promote the methionine-dependent reprogramming of glioblastoma cells towards pluripotency. 38
31395852 2019
24
A lateral approach to the feline cerebellar fossa: case report and identification of an external landmark for the tentorium ossium. 38
31418626 2019
25
Metabolomic profiling of blood plasma in patients with primary brain tumours: Basal plasma metabolites correlated with tumour grade and plasma biomarker analysis predicts feasibility of the successful statistical discrimination from healthy subjects - a preliminary study. 38
31419008 2019
26
Eye Tracking for Deep Learning Segmentation Using Convolutional Neural Networks. 38
31044392 2019
27
Intradural Transpetrosectomy for Petrous Apex Meningiomas. 38
31392875 2019
28
Smoking status and perioperative adverse events in patients undergoing cranial tumor surgery. 38
31183602 2019
29
Primary central nervous system tumor treatment and survival in the United States, 2004-2015. 38
31254264 2019
30
Efficacy and safety of fractionated conformal radiation therapy in acromegaly: a long-term follow-up study. 38
31098940 2019
31
Clinical presentation and long-term outcome of primary spinal intradural malignant peripheral nerve sheath tumors. 38
31421588 2019
32
Multidisciplinary team efforts improve the surgical outcomes of sellar region lesions during pregnancy. 38
31422527 2019
33
Study Protocol for a Randomized Controlled Trial Evaluating the Efficacy of an Evidence-Based iPad-App for Cognitive Rehabilitation in Patients with Primary Brain Tumors. 38
29917115 2019
34
Clinical, radiological, and histopathological predictors for long-term prognosis after surgery for atypical meningiomas. 38
31147831 2019
35
[Guillain-Barre syndrome complicated on post-operation with renal carcinoma and meningioma: a case report]. 38
31420639 2019
36
Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines. 38
31382694 2019
37
Spinal Versus Intracranial Meningioma: Aberrant Expression of CD10 and Inhibin with Relation to Clinicopathological Features and Prognosis. 38
31372897 2019
38
[Treatment of benign tumors in thoracic spinal canal by modified replanting posterior ligament complex applying piezoelectric osteotomy]. 38
31407559 2019
39
Neurofibromatosis type 2 and related disorders. 38
31425178 2019
40
Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. 38
30993672 2019
41
Management of pediatric CNS meningiomas: CCHE-57357 experience in 39 cases. 38
31127346 2019
42
Comparison of machine learning classifiers for differentiation of grade 1 from higher gradings in meningioma: A multicenter radiomics study. 38
31425811 2019
43
Whole-tumor histogram analysis of DWI and QSI for differentiating between meningioma and schwannoma: a pilot study. 38
31396824 2019
44
A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. 38
31301014 2019
45
[Management of tumoral epilepsy in meningioma surgery: Review of the literature and survey of French national practices]. 38
31100348 2019
46
Subjective cognitive functioning in patients with a meningioma: Its course and association with objective cognitive functioning and psychological symptoms. 38
31141624 2019
47
Large dural-based mass with bony hyperostosis in a 16-year-old male: IgG4-related disease mimicking lymphoplasmacyte-rich meningioma. 38
31073682 2019
48
Challenging the concept that late recurrence and death from tumor are common after fractionated radiotherapy for benign meningioma. 38
31071515 2019
49
A contemporary and a historical patient with an ectopic meningioma. 38
29490576 2019
50
Multiple primary intraosseous meningioma mimicking fibrous dysplasia: a case report. 38
31380701 2019

Variations for Lymphoplasmacyte-Rich Meningioma

Expression for Lymphoplasmacyte-Rich Meningioma

Search GEO for disease gene expression data for Lymphoplasmacyte-Rich Meningioma.

Pathways for Lymphoplasmacyte-Rich Meningioma

Pathways related to Lymphoplasmacyte-Rich Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.99 SDC1 CD79A CD68 CD163
2 10.81 CD68 CD163

GO Terms for Lymphoplasmacyte-Rich Meningioma

Cellular components related to Lymphoplasmacyte-Rich Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 SDC1 CD79A CD163

Sources for Lymphoplasmacyte-Rich Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....